218 related articles for article (PubMed ID: 29721479)
1. Practical consensus recommendations on management of triple-negative metastatic breast cancer.
Rangarao R; Smruti BK; Singh K; Gupta A; Batra S; Choudhary RK; Gupta A; Sahani S; Kabra V; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):127-131. PubMed ID: 29721479
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
3. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.
Zeichner SB; Terawaki H; Gogineni K
Breast Cancer (Auckl); 2016; 10():25-36. PubMed ID: 27042088
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
5. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
Landry I; Sumbly V; Vest M
Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
7. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
9. Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists' Perspective.
Li S; Bao C; Huang L; Wei JF
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294342
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
11. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
Vaid AK; Deshmukh C; Rohatgi N; Ghosh J
Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197
[TBL] [Abstract][Full Text] [Related]
12. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
13. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
14. The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review.
Jiang MP; Huang X; Yin YM; Tang JH
Ann Transl Med; 2022 Aug; 10(16):907. PubMed ID: 36111045
[TBL] [Abstract][Full Text] [Related]
15. Management of advanced breast cancer with the epothilone B analog, ixabepilone.
Gradishar W
Drug Des Devel Ther; 2009 Sep; 3():163-71. PubMed ID: 19920932
[TBL] [Abstract][Full Text] [Related]
16. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline
Alaklabi S; Roy AM; Chaudhary LN; Gandhi S
Explor Target Antitumor Ther; 2023; 4(6):1301-1309. PubMed ID: 38213539
[TBL] [Abstract][Full Text] [Related]
17. Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
Basade M; Singhal M; Rathi AK; Nandi M; Minhas S; Goswami C; Shinde S; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):146-150. PubMed ID: 29721483
[TBL] [Abstract][Full Text] [Related]
18. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.
André F; Zielinski CC
Ann Oncol; 2012 Aug; 23 Suppl 6():vi46-51. PubMed ID: 23012302
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: an unmet medical need.
Hudis CA; Gianni L
Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
[TBL] [Abstract][Full Text] [Related]
20. Target-Oriented Classification of Triple-negative Breast Cancer.
Mizumoto S; Inubushi S; Miki M; Nakamura H; Baba M; Yamashita Y; Yamamoto M; Inoue S; Tanino H; Kunihisa T
Anticancer Res; 2023 Nov; 43(11):5067-5072. PubMed ID: 37909966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
